سعر فيزجو 600مجم/600مجم/20.000وحدة 10 مل 2024

Phesgo fixed-dose pertuzumab/trastuzumab/hyaluronidase solution for subcutaneous injection, single vial 10 mL (600 mg/600 mg/20,000 units per 10 mL); HER2-targeted therapy.

• HER2-positive early breast cancer with chemotherapy: neoadjuvant treatment (locally advanced, inflammatory or early stage >2 cm or node positive) and adjuvant treatment at high risk of recurrence.Population: AdultsDailyMed (U.S. National Library of Medicine)
• HER2-positive metastatic breast cancer in combination with docetaxel in patients without prior anti-HER2 therapy or chemotherapy for metastatic disease.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>30%) in early breast cancer: alopecia, nausea, diarrhea, anemia and asthenia.International label, same product · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase or any excipient.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: cardiomyopathy (evaluate cardiac function before and during treatment), embryo-fetal toxicity (effective contraception needed) and pulmonary toxicity.International label, same product · DailyMed (U.S. National Library of Medicine)

• No information on presence in human milk; weigh breastfeeding benefits against maternal need, considering the 7-month trastuzumab washout period.International label, same product · DailyMed (U.S. National Library of Medicine)

English text not available for this section.